Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cell injection (Changchun Tuohua Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Changchun Tuohua Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord mesenchymal stem cell injection is an allogeneic cell therapy developed by Changchun Tuohua Pharmaceutical for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) of infectious etiology. The therapy consists of mesenchymal stem cells derived from human umbilical cord tissue, which are administered intravenously to leverage their immunomodulatory and anti-inflammatory properties. These cells are designed to address the systemic cytokine storm and acute lung injury associated with ARDS by secreting paracrine factors that modulate immune cell activity and promote tissue repair. The product has been certified by China's National Institutes for Food and Drug Control and is currently being evaluated in a Phase I/II dose-escalation clinical trial focusing on safety, tolerability, and preliminary efficacy in patients with non-COVID-19 infectious ARDS.
- Other names
- hUC-MSC injectionhuman umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cell injection (Changchun Tuohua Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cell injection (Changchun Tuohua Pharmaceutical).